Company name Akari Therapeutics, Plc
Stock symbol AKTX
Class period March 30, 2017 and May 11, 2017
Lead plaintiff deadline July 11, 2017
Court Southern District of New York
Status Under Investigation

NEW YORK, May 16, 2017 – Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who acquired Akari Therapeutics, Plc (NASDAQ: AKTX) securities between March 30, 2017 and May 11, 2017 (the “Class Period”).

According to the Complaint, throughout the Class Period, Akari made materially false and/or misleading statements, and/or failed to disclose that: Chief Executive Officer Dr. Gur Roshwalb and possibly other executives were involved in publishing false information about the Company, including false information about the Phase 2 PNH trial of Coversin; that Akari lacked adequate checks and protections to prevent such behavior; and that as a result of the above, the Company’s statements about its business, operations, and prospects were false and misleading and/or lacked a reasonable basis.

On May 11, 2017, Akari announced that Dr. Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved in a materially inaccurate research report that was released and subsequently withdrawn in April 26, 2017 by Edison Investment Research Ltd. When this information was released, Akari shares lowered in value materially, which harmed investors according to the Complaint.

If you purchased or otherwise acquired Akari securities during the Class Period and suffered a loss or continue to hold shares purchased prior to the Class Period, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.

Join the action by filling out the form below

First name*

Last name*

City, state ZIP code*

Email address*

Daytime phone*

Evening phone

Purchase Date*

No. of Shares*

Purchase Price*

Purchase Date

No. of Shares

Purchase Price

Join action?*
YesNo


Call to provide more information: Tel: (212) 308-5858

Please list below any additional transactions in this security:

Additional comments

The submission of this form does not create an attorney-client relationship, nor any obligation on the part of Bragar Eagel & Squire, P.C., or you to file a legal action. Any information you submit will be maintained as confidential. If Bragar Eagel & Squire, P.C., in its sole discretion, believes that you might be an appropriate class representative, Bragar Eagel & Squire, P.C., will contact you to discuss the matter and to determine whether to establish an attorney client relationship.